Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $240.00 by Analysts at Morgan Stanley

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price decreased by Morgan Stanley from $300.00 to $240.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley‘s price objective indicates a potential upside of 42.90% from the stock’s previous close.

Several other equities research analysts also recently weighed in on ALNY. Jefferies Financial Group increased their price target on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a “hold” rating in a report on Tuesday, September 8th. TD Cowen reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Alnylam Pharmaceuticals in a report on Thursday. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Finally, Zacks Research lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $325.50.

Alnylam Pharmaceuticals Trading Down 3.5%

ALNY stock traded down $6.05 on Friday, reaching $167.95. The company’s stock had a trading volume of 3,274,349 shares, compared to its average volume of 1,500,848. Alnylam Pharmaceuticals has a 12-month low of $167.16 and a 12-month high of $479.79. The firm has a market cap of $22.47 billion, a PE ratio of 31.22 and a beta of 0.28. The business has a fifty day simple moving average of $237.78 and a two-hundred day simple moving average of $287.22. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, beating the consensus estimate of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the prior year, the firm earned $2.90 EPS. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. As a group, research analysts forecast that Alnylam Pharmaceuticals will post 6.43 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president directly owned 12,807 shares in the company, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. SCS Capital Management LLC bought a new position in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $34,784,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $50,773,000. Silvant Capital Management LLC bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at $5,456,000. WINTON GROUP Ltd bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at $2,372,000. Finally, Wealthfront Advisers LLC acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $2,876,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q3 results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, ahead of estimates. The company maintained its fiscal 2026 net product-sales outlook. Alnylam Q3 earnings and revenue results
• Positive Sentiment: Long-term pipeline prospects remain supportive. Alnylam expects $4.2 billion-$4.5 billion in 2026 TTR sales and expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an expected launch timeline around 2030. Alnylam TTR sales and TRITON-CM update
• Neutral Sentiment: Analysts remain divided. Wells Fargo lowered its target to $220 and kept an “equal weight” rating; RBC cut its target to $280 but retained “outperform”; and Needham reduced its target to $243 while maintaining “buy.” These targets still imply substantial potential upside from recent levels.
• Negative Sentiment: Demand growth is the immediate concern. Slower U.S. Amvuttra patient starts and moderating Amvuttra and Onpattro sales growth raised questions about the pace of commercial expansion despite the quarterly beat. Alnylam demand growth concerns
• Negative Sentiment: Broker sentiment weakened. Bernstein downgraded Alnylam to “market perform” with a $199 target, while Stifel cut its rating to “hold” and set a $225 target. The reductions reflect greater caution around near-term growth and valuation.
• Negative Sentiment: Additional risk overhangs remain. An investor law firm announced an investigation related to a prior company disclosure, potentially adding to market uncertainty, although no wrongdoing has been established. Alnylam investor investigation

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.